Stakeholder Opinions: Non-Hodgkins Lymphoma - Immunotherapy Stimulates the
Market
Introduction
- The disproportionate rise in non-Hodgkins Lymphoma (NHL) incidence over
the last 40 years remains largely unexplained. Treatment options have been
revolutionized by the introduction of monoclonal antibody technology.
Building on the foundations established by Rituxan, and integrating novel
immunotherapeutic technologies into clinical practice, will provide the
platform for ongoing advancement.
Scope of this report
- Overview of NHL including epidemiology, etiology, clinical features,
staging and prognostic variables
- Current treatment controversies and novel therapies in the developmental
pipeline
- Analysis of trial data, marketing factors and commercial potential for key
technologies in late-stage clinical development
- Stakeholder opinions and interview transcripts based on qualitative
interviews with six opinion leaders in the US and Europe
Research and analysis highlights
- NHL is one of the few malignancies in which there continues to be a rise
in incidence, exemplified by the more than 40% increase in reported cases of
NHL in the last forty years. The reasons for the disproportionate increase
in NHL incidence remains an area of intense speculation and debate.
- The introduction of Genentech/Roches Rituxan has revolutionized NHL
treatment. However, controversy persists regarding how to optimally
integrate this technology into existing treatment paradigms, both in terms
of dose and dosing frequency. Future immunotherapy-based treatments will be
enhanced by the radioimmunoconjugates and vaccine therapy.
- Gene expression profiling using DNA microarrays has the potential to
greatly enhance NHL prognostication and guide treatment decisions. However,
the full benefits of this technology will only be realized when the
available treatments are sophisticated enough to deliver more efficacious
therapy to individuals diagnosed with poor prognosis disease.
Key reasons to read this report
- Identify the areas of unmet need and clinical controversy in NHL treatment
- Understand how future advancements in NHL diagnostics have the potential
to shift the treatment paradigm
- Assess opportunities and risks for innovative treatments targeting NHL
treatment
View Cart
